Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Investigation of silver nanoparticles on titanium surface created by ion implantation technology.

Lampé I, Beke D, Biri S, Csarnovics I, Csik A, Dombrádi Z, Hajdu P, Hegedűs V, Rácz R, Varga I, Hegedűs C.

Int J Nanomedicine. 2019 Jul 1;14:4709-4721. doi: 10.2147/IJN.S197782. eCollection 2019.

2.

Creatine Supplementation Supports the Rehabilitation of Adolescent Fin Swimmers in Tendon Overuse Injury Cases.

Juhasz I, Kopkane JP, Hajdu P, Szalay G, Kopper B, Tihanyi J.

J Sports Sci Med. 2018 May 14;17(2):279-288. eCollection 2018 Jun.

3.

A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.

Chimote AA, Balajthy A, Arnold MJ, Newton HS, Hajdu P, Qualtieri J, Wise-Draper T, Conforti L.

Sci Signal. 2018 Apr 24;11(527). pii: eaaq1616. doi: 10.1126/scisignal.aaq1616.

4.

The C-terminal HRET sequence of Kv1.3 regulates gating rather than targeting of Kv1.3 to the plasma membrane.

Voros O, Szilagyi O, Balajthy A, Somodi S, Panyi G, Hajdu P.

Sci Rep. 2018 Apr 12;8(1):5937. doi: 10.1038/s41598-018-24159-8.

5.

Sterol Regulation of Voltage-Gated K+ Channels.

Balajthy A, Hajdu P, Panyi G, Varga Z.

Curr Top Membr. 2017;80:255-292. doi: 10.1016/bs.ctm.2017.05.006. Epub 2017 Jul 24. Review.

PMID:
28863820
6.

Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer.

Chimote AA, Hajdu P, Sfyris AM, Gleich BN, Wise-Draper T, Casper KA, Conforti L.

Cancer Res. 2017 Jan 1;77(1):53-61. doi: 10.1158/0008-5472.CAN-16-2372. Epub 2016 Nov 4.

7.

7DHC-induced changes of Kv1.3 operation contributes to modified T cell function in Smith-Lemli-Opitz syndrome.

Balajthy A, Somodi S, Pethő Z, Péter M, Varga Z, Szabó GP, Paragh G, Vígh L, Panyi G, Hajdu P.

Pflugers Arch. 2016 Aug;468(8):1403-18. doi: 10.1007/s00424-016-1851-4. Epub 2016 Jun 17.

PMID:
27315086
8.

Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype.

Chimote AA, Hajdu P, Kottyan LC, Harley JB, Yun Y, Conforti L.

J Autoimmun. 2016 May;69:86-93. doi: 10.1016/j.jaut.2016.03.004. Epub 2016 Mar 16.

9.

The C-terminus SH3-binding domain of Kv1.3 is required for the actin-mediated immobilization of the channel via cortactin.

Hajdu P, Martin GV, Chimote AA, Szilagyi O, Takimoto K, Conforti L.

Mol Biol Cell. 2015 May 1;26(9):1640-51. doi: 10.1091/mbc.E14-07-1195. Epub 2015 Mar 4.

10.

Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels.

Bartok A, Toth A, Somodi S, Szanto TG, Hajdu P, Panyi G, Varga Z.

Toxicon. 2014 Sep;87:6-16. doi: 10.1016/j.toxicon.2014.05.002. Epub 2014 May 28.

PMID:
24878374
11.

Fast camera studies at an electron cyclotron resonance table plasma generator.

Rácz R, Biri S, Hajdu P, Pálinkás J.

Rev Sci Instrum. 2014 Feb;85(2):02A507. doi: 10.1063/1.4847215.

PMID:
24593430
12.

Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells.

Chimote AA, Hajdu P, Kucher V, Boiko N, Kuras Z, Szilagyi O, Yun YH, Conforti L.

J Immunol. 2013 Dec 15;191(12):6273-80. doi: 10.4049/jimmunol.1300702. Epub 2013 Nov 13.

13.

Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity.

Hajdu P, Chimote AA, Thompson TH, Koo Y, Yun Y, Conforti L.

Biomaterials. 2013 Dec;34(38):10249-57. doi: 10.1016/j.biomaterials.2013.09.019. Epub 2013 Sep 27.

14.

The role of PSD-95 in the rearrangement of Kv1.3 channels to the immunological synapse.

Szilágyi O, Boratkó A, Panyi G, Hajdu P.

Pflugers Arch. 2013 Sep;465(9):1341-53. doi: 10.1007/s00424-013-1256-6. Epub 2013 Apr 4.

PMID:
23553419
15.

Analysis of the K+ current in human CD4+ T lymphocytes in hypercholesterolemic state.

Somodi S, Balajthy A, Szilágyi O, Pethő Z, Harangi M, Paragh G, Panyi G, Hajdu P.

Cell Immunol. 2013 Jan;281(1):20-6. doi: 10.1016/j.cellimm.2013.01.004. Epub 2013 Jan 29.

PMID:
23416720
16.

Membrane microdomain organization, calcium signal, and NFAT activation as an important axis in polarized Th cell function.

Izsepi E, Himer L, Szilagyi O, Hajdu P, Panyi G, Laszlo G, Matko J.

Cytometry A. 2013 Feb;83(2):185-96. doi: 10.1002/cyto.a.22234. Epub 2012 Nov 26.

17.

Voltage-gated sodium channel Nav1.7 maintains the membrane potential and regulates the activation and chemokine-induced migration of a monocyte-derived dendritic cell subset.

Kis-Toth K, Hajdu P, Bacskai I, Szilagyi O, Papp F, Szanto A, Posta E, Gogolak P, Panyi G, Rajnavolgyi E.

J Immunol. 2011 Aug 1;187(3):1273-80. doi: 10.4049/jimmunol.1003345. Epub 2011 Jun 29.

18.

Answer to the "comment on functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse" by Stefan Bittner et al. [Immunol. Lett. 125 (Aug 15 (2)) (2009) 156-157].

Hajdú P, Szilágyi O, Tóth A, Krasznai Z, Pocsai K, Panyi G.

Immunol Lett. 2010 Mar 10;129(1):47-9. doi: 10.1016/j.imlet.2009.12.026. Epub 2010 Jan 15. No abstract available.

PMID:
20079762
19.

Ion channels in T lymphocytes: an update on facts, mechanisms and therapeutic targeting in autoimmune diseases.

Varga Z, Hajdu P, Panyi G.

Immunol Lett. 2010 May 4;130(1-2):19-25. doi: 10.1016/j.imlet.2009.12.015. Epub 2009 Dec 21. Review.

PMID:
20026117
20.

Developmental switch of the expression of ion channels in human dendritic cells.

Zsiros E, Kis-Toth K, Hajdu P, Gaspar R, Bielanska J, Felipe A, Rajnavolgyi E, Panyi G.

J Immunol. 2009 Oct 1;183(7):4483-92. doi: 10.4049/jimmunol.0803003. Epub 2009 Sep 11.

21.

Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse.

Tóth A, Szilágyi O, Krasznai Z, Panyi G, Hajdú P.

Immunol Lett. 2009 Jun 30;125(1):15-21. doi: 10.1016/j.imlet.2009.05.004. Epub 2009 May 27.

PMID:
19477198
22.

Effects of changes in extracellular pH and potassium concentration on Kv1.3 inactivation.

Somodi S, Hajdu P, Gáspár R, Panyi G, Varga Z.

Eur Biophys J. 2008 Sep;37(7):1145-56. doi: 10.1007/s00249-008-0267-2. Epub 2008 Jan 24.

PMID:
18214462
23.

Involvement of membrane channels in autoimmune disorders.

Varga Z, Hajdu P, Panyi G, Gáspár R, Krasznai Z.

Curr Pharm Des. 2007;13(24):2456-68. Review.

PMID:
17692013
24.
25.

Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric energy transfer study.

Rubovszky B, Hajdú P, Krasznai Z, Gáspár R Jr, Waldmann TA, Damjanovich S, Bene L.

Eur Biophys J. 2005 Mar;34(2):127-43.

PMID:
15375639
26.

pH-dependent modulation of Kv1.3 inactivation: role of His399.

Somodi S, Varga Z, Hajdu P, Starkus JG, Levy DI, Gáspár R, Panyi G.

Am J Physiol Cell Physiol. 2004 Oct;287(4):C1067-76. Epub 2004 Jun 16.

27.

Positive inotropic effect of the inhibition of cyclic GMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase (PDE2) on guinea pig left atria in eu- and hyperthyroidism.

Gesztelyi R, Zsuga J, Hajdú P, Szabó JZ, Cseppento A, Szentmiklósi AJ.

Gen Physiol Biophys. 2003 Dec;22(4):501-13.

28.

New phenotypic, functional and electrophysiological characteristics of KG-1 cells.

Hajas G, Zsiros E, László T, Hajdú P, Somodi S, Réthi B, Gogolák P, Ludányi K, Panyi G, Rajnavölgyi E.

Immunol Lett. 2004 Mar 29;92(1-2):97-106.

PMID:
15081533
29.

Drug- and mutagenesis-induced changes in the selectivity filter of a cardiac two-pore background K+ channel.

Hajdú P, Ulens C, Panyi G, Tytgat J.

Cardiovasc Res. 2003 Apr 1;58(1):46-54.

PMID:
12667945
30.

Cholesterol modifies the gating of Kv1.3 in human T lymphocytes.

Hajdú P, Varga Z, Pieri C, Panyi G, Gáspár R Jr.

Pflugers Arch. 2003 Mar;445(6):674-82. Epub 2003 Jan 18.

PMID:
12632187
31.

Public health challenges of the 21st century and the role of schools of public health in Central and Eastern Europe.

Adány R, Hajdú PV, Székes G, Vokó Z, Kósa K.

Public Health Rev. 2002;30(1-4):15-33. No abstract available.

PMID:
12613695
32.

Two novel toxins from the Amazonian scorpion Tityus cambridgei that block Kv1.3 and Shaker B K(+)-channels with distinctly different affinities.

Batista CV, Gómez-Lagunas F, Rodríguez de la Vega RC, Hajdu P, Panyi G, Gáspár R, Possani LD.

Biochim Biophys Acta. 2002 Dec 16;1601(2):123-31.

PMID:
12445473
33.

Effects of toxins Pi2 and Pi3 on human T lymphocyte Kv1.3 channels: the role of Glu7 and Lys24.

Péter M Jr, Varga Z, Hajdu P, Gáspár R Jr, Damjanovich S, Horjales E, Possani LD, Panyi G.

J Membr Biol. 2001 Jan 1;179(1):13-25.

PMID:
11155206
34.

Blockage of human T lymphocyte Kv1.3 channels by Pi1, a novel class of scorpion toxin.

Péter M Jr, Hajdu P, Varga Z, Damjanovich S, Possani LD, Panyi G, Gáspár R Jr.

Biochem Biophys Res Commun. 2000 Nov 11;278(1):34-7.

PMID:
11071851
35.

Avoidable mortality. Is it an indicator of quality of medical care in eastern European countries?

Bojan F, Hajdu P, Belicza E.

Qual Assur Health Care. 1991;3(3):191-203.

PMID:
1782387
36.

Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Brockmeier D, Hajdù P, Henke W, Mutschler E, Palm D, Rupp W, Spahn H, Verho MT, Wellstein A.

Eur J Clin Pharmacol. 1988;35(6):613-23.

PMID:
2906875
37.

Direct assay of conjugates of penbutolol and its metabolites in urine.

Lehr KH, Damm P, Hajdù P.

Arzneimittelforschung. 1987 Dec;37(12):1373-5.

PMID:
3449064
38.

Isolation, identification and in vitro synthesis of conjugates of penbutolol and its metabolites.

Lehr KH, Damm P, Fehlhaber HW, Hajdù P.

Arzneimittelforschung. 1987 Nov;37(11):1222-4.

PMID:
3440029
39.

Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.

Malerczyk V, Maass L, Verho M, Hajdú P, Klesel N, Rangoonwala R.

Infection. 1987 May-Jun;15(3):211-4.

PMID:
3610330
40.

Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.

Maass L, Malerczyk V, Verho M, Hajdú P, Seeger K, Klesel N.

Infection. 1987 May-Jun;15(3):202-6.

PMID:
3610328
41.

Influence of renal function on the pharmacokinetics of ramipril (HOE 498).

Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jané F, Kuan TS, Mora J, Walter U, Eckert HG, Hajdú P, et al.

Am J Cardiol. 1987 Apr 24;59(10):70D-78D.

PMID:
3034037
42.

Pharmacokinetics of ramipril in the elderly.

Meyer BH, Müller FO, Badian M, Eckert HG, Hajdú P, Irmisch R, Schmidt D.

Am J Cardiol. 1987 Apr 24;59(10):33D-37D.

PMID:
3034031
44.

Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.

Dagrosa EE, Hajdú P, Malerczyk V, de Looze S, Seeger K, Grötsch H.

Clin Ther. 1987;10(1):18-31. Erratum in: Clin Ther 1988;10(4):466.

PMID:
3450392
45.

Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Ochs HR, Hajdú P, Greenblatt DJ.

Klin Wochenschr. 1986 Jul 15;64(14):636-41.

PMID:
3762014
46.

Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.

Spahn H, Kirch W, Hajdu P, Mutschler E, Ohnhaus EE.

Eur J Clin Pharmacol. 1986;29(5):555-60.

PMID:
3956561
47.

Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.

Dagrosa EE, Verho M, Malerczyk V, de Looze S, Hajdú P, Toyodera K.

Clin Ther. 1986;8(6):632-45.

PMID:
3466701
48.

The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.

Bussien JP, Nussberger J, Porchet M, Waeber B, Brunner HR, Perisic M, Tansey MJ, Bomm M, Hajdu P.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Mar;329(1):63-9.

PMID:
2987705
49.

Pharmacokinetics of pheniramine (Avil) and metabolites in healthy subjects after oral and intravenous administration.

Witte PU, Irmisch R, Hajdú P.

Int J Clin Pharmacol Ther Toxicol. 1985 Jan;23(1):59-62.

PMID:
3988394
50.

Supplemental Content

Support Center